Aris Bechlioulis

Dr. Aris Bechlioulis

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Therapeutic Advances in Cardiovascular Disease
Verified
Journal Article
Open access
PDF file
SGSophia Giannitsi
Sophia Giannitsi
MBMara Bougiakli
Mara Bougiakli
ABAris Bechlioulis
Aris Bechlioulis
AKAnna Kotsia
Anna Kotsia
LMLampros K. Michalis
Lampros K. Michalis
KNKaterina K. Naka
Katerina K. Naka
Reduced functional ability and exercise tolerance in patients with heart failure (HF) are associated with poor quality of life and a worse prognosis. The 6-minute walking test (6MWT) is a widely available and well-tolerated test for the assessment of the functional capacity of patients with HF. Although the cardiopulmonary exercise test (a maximal exercise test) remains the gold standard for the evaluation of exercise capacity in patients with HF, the 6MWT (submaximal exercise test) may provide reliable information about the patient’s daily activity. The current review summarizes the value of 6MWT in patients with HF and identifies its usefulness and limitations in everyday clinical practice in populations of HF. We aimed to investigate potential associations of 6MWD with other measures of functional status and determinants of 6MWD in patients with HF as well as to review its prognostic role and changes to various interventions in these patients.

12 October 2012 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
KNKaterina K. Naka
Katerina K. Naka
KPKaterina Papathanassiou
Katerina Papathanassiou
ABAris Bechlioulis
Aris Bechlioulis
NKNikolaos Kazakos
Nikolaos Kazakos
KPKonstantinos Pappas
Konstantinos Pappas
LMLampros Michalis
Lampros Michalis
Background: Type 2 diabetes mellitus (T2DM) is independently associated with an increased risk for cardiovascular diseases that is primarily due to the early development of advanced atherosclerotic vascular changes. The aim of our study was to investigate the predictors of vascular dysfunction in T2DM patients.Methods: We studied 165 T2DM patients without known macrovascular or microvascular disease. Standard demographic (age, gender, cardiovascular risk factors, medications), clinical (body mass index, blood pressure) and laboratory (glucose, glycated hemoglobin, lipids, renal function) parameters were included in analyses. Brachial artery flow-mediated dilation (FMD), nitrate mediated dilation (NMD) and Carotid-Femoral Pulse Wave Velocity (PWV) were measured.Results: Median age was 66 years and duration since T2DM diagnosis was 10 years, 70% were females and 79% hypertensives, while only 10% had a glycated hemoglobin <7%. FMD was positively associated with NMD (r 0.391, P < 0.001), while PWV was inversely associated with FMD (r -0.218, P = 0.014) and NMD (r -0.309, P < 0.001). Time since diagnosis of diabetes was the single independent predictor of FMD (β -0.40, P = 0.003). Increased age and fasting glucose and the presence of hypertension were independent predictors of decreased NMD (P < 0.001). Increased age and systolic blood pressure were independently associated with increased PWV (P < 0.001).Conclusions: In T2DM patients, impairment of endothelium-dependent vasodilation was independently associated only with longer diabetes duration while no association with other established risk factors was found. Vascular smooth muscle dysfunction and increased arterial stiffness were more prominent in older T2DM patients with hypertension. Worse glycemic control was associated with impaired vascular smooth muscle function.

10 October 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
DPDafni K. Plati
Dafni K. Plati
Evanthia Eleftherios TripolitiEvanthia Eleftherios Tripoliti
Evanthia Eleftherios Tripoliti
ABAris Bechlioulis
Aris Bechlioulis
ARAidonis Rammos
Aidonis Rammos
IDIliada Dimou
Iliada Dimou
Dimitrios FotiadisDimitrios Fotiadis
Dimitrios Fotiadis
The aim of this study was to address chronic heart failure (HF) diagnosis with the application of machine learning (ML) approaches. In the present study, we simulated the procedure that is followed in clinical practice, as the models we built are based on various combinations of feature categories, e.g., clinical features, echocardiogram, and laboratory findings. We also investigated the incremental value of each feature type. The total number of subjects utilized was 422. An ML approach is proposed, comprising of feature selection, handling class imbalance, and classification steps. The results for HF diagnosis were quite satisfactory with a high accuracy (91.23%), sensitivity (93.83%), and specificity (89.62%) when features from all categories were utilized. The results remained quite high, even in cases where single feature types were employed.

3 July 2013 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
AVAntonios P. Vlahos
Antonios P. Vlahos
KNKaterina K. Naka
Katerina K. Naka
ABAris Bechlioulis
Aris Bechlioulis
PTParaskevi Theoharis
Paraskevi Theoharis
KVKonstantinos Vakalis
Konstantinos Vakalis
HMHaralampos J. Milionis
Haralampos J. Milionis

Verified
Journal Article
Open access
PDF file
FBFotios Barkas
Fotios Barkas
CSChrysoula-Paraskevi Styla
Chrysoula-Paraskevi Styla
ABAris Bechlioulis
Aris Bechlioulis
HMHaralampos Milionis
Haralampos Milionis
Evangelos LiberopoulosEvangelos Liberopoulos
Evangelos Liberopoulos
Background: Although remdesivir treatment is widely used during the pandemic coronavirus disease 2019 (COVID-19), there is scarce evidence regarding its cardiac side effects. Case presentation: We report the case of a 36-year-old male hospitalized due to severe COVID-19 symptoms. He presented with a 10-day history of fever (up to 39.7 °C), productive cough, hemoptysis, fatigue, myalgias and hypoxemia. The patient received supplemental oxygen, dexamethasone, remdesivir and empirical antibiotic treatment according to protocol. Asymptomatic sinus bradycardia developed on hospital day 3 (namely, heart rate 39/min compared to 92/min on admission). Secondary causes of bradycardia were excluded based on the absence of relevant evidence from laboratory work-up and echocardiographic examination. The patient’s rhythm restored to normal 9 days after the discontinuation of remdesivir. Conclusions: Considering the frequent use of remdesivir in patients with COVID-19, physicians should be aware of this possible adverse event.

5 November 2019 in Electronics
Verified
Journal Article
Open access
PDF file
GBGeorge Baldoumas
George Baldoumas
DPDimitrios Peschos
Dimitrios Peschos
GTGiorgos Tatsis
Giorgos Tatsis
Spyridon K ChronopoulosSpyridon K Chronopoulos
Spyridon K Chronopoulos
Vasilis ChristofilakisVasilis Christofilakis
Vasilis Christofilakis
KNKaterina K. Naka
Katerina K. Naka
In this paper, a prototype photoplethysmography (PPG) electronic device is presented for the distinction of individuals with congestive heart failure (CHF) from the healthy (H) by applying the concept of Natural Time Analysis (NTA). Data were collected simultaneously with a conventional three-electrode electrocardiography (ECG) system and our prototype PPG electronic device from H and CHF volunteers at the 2nd Department of Cardiology, Medical School of Ioannina, Greece. Statistical analysis of the results show a clear separation of CHF from H subjects by means of NTA for both the conventional ECG system and our PPG prototype system, with a clearly better distinction for the second one which additionally inherits the advantages of a low-cost portable device.